Company intelligence / Profile preview

Beijing Hwealth Bio-Pharmaceutical

Beijing, Beijing, Chinabeehall.en.made-in-china.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company has several programs in early clinical development, including small molecules and herbal medicines targeting obesity, HER2-negative breast cancer, and metabolic diseases. Paclitaxel is approved for use in China and the US. No recent late-stage or pivotal trial results are reported.

Therapeutic areas: OncologyEndocrinology
Modalities: Small moleculeHerbal medicine
Industry: Biotech

Beyond the preview

Go deeper on Beijing Hwealth Bio-Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Hwealth Bio-Pharmaceutical.

Explore the full profile